• MDockPeP2_VS: Peptide Inhibitors of β-Lactamase

  2026-09-16

  The 2024 PNAS Nexus study introduces MDockPeP2_VS, an automated structure-based method that reduces the conformational search problem in large-scale peptide screening. Applied to TEM-1 β-lactamase, the workflow identified a short peptide with micromolar inhibitory activity, illustrating how computational peptide discovery can support β-lactam antibiotic resistance research.

• GANT61 Workflows for GLI-Driven Cancer Research

  2026-09-16

  GANT61 provides a practical way to test whether GLI1/GLI2 activity sustains malignant phenotypes, ferroptosis resistance, or chemotherapy tolerance. This guide connects formulation, dose-response design, GLI2–PRDX1 mechanism testing, combination assays, and tumor-model translation.

• Magneto-Piezoelectric Scaffolds for Infectious Bone Repair

  2026-09-15

  This ACS Nano study developed a dual-responsive scaffold that combines biofilm disruption with immune-metabolic stimulation for infectious bone defect repair. Its central advance is the targeted activation of oxidative phosphorylation in Icam1+ macrophages through sequential magnetic and ultrasound cues, linking JAK2-STAT3 signaling to improved osteogenic and proangiogenic repair.

• Gefitinib in Gastric Cancer Assembloid Assays

  2026-09-15

  Gefitinib (ZD1839) is a potent EGFR inhibitor whose effects can change substantially when tumor cells are tested with patient-matched stromal populations. This guide translates recent gastric cancer assembloid findings into practical assay decisions for pathway engagement, resistance analysis, and biologically interpretable drug screening.

• CHIR-99021 for Stem Cell and WNT Assays

  2026-09-14

  CHIR-99021 (CT99021) gives researchers a selective way to perturb GSK-3 while tuning pluripotency, lineage differentiation, and WNT-responsive degradation assays. This guide connects practical dosing and storage decisions with the KIF26B reporter strategy described in the reference study.

• Ginsenoside Rb1, Wnt Signaling, and Stroke Injury

  2026-09-14

  Liu et al. show that ginsenoside Rb1 limits cerebral ischemia-reperfusion injury by activating Wnt/β-catenin signaling and shifting microglia toward an anti-inflammatory phenotype. Using complementary mouse and BV2-cell models, the study links pathway activation to improved perfusion, smaller infarcts, and better neurological outcomes, while pharmacological pathway inhibition weakens these effects.

• Proteomimetics Target SARS-CoV-2 S-RBD/hACE2

  2026-09-13

  The reference study presents a structure-guided strategy for converting key hACE2 recognition elements into constrained proteomimetics that disrupt the SARS-CoV-2 Spike receptor-binding domain interaction. Its lead construct, compound 28, combined helical and β-sheet mimetics, inhibited pseudovirus entry, and showed stability and low epithelial permeability consistent with potential intranasal delivery.

• Berberine Hydrochloride: Metabolic and Bone Research

  2026-09-12

  Berberine hydrochloride is an isoquinoline alkaloid used in metabolic, antimicrobial, apoptosis, ferroptosis, and gut–bone research. Current evidence supports AMPK-centered cellular studies and a preclinical gut–bone mechanism, but it does not establish a clinical type 2 diabetes mellitus treatment or osteoporosis indication.

• Ertugliflozin (PF-04971729): From Transporter to Outcomes

  2026-09-11

  Ertugliflozin (PF-04971729) connects selective renal glucose reabsorption inhibition with cardiorenal outcome research. This evidence-first guide shows how to align transporter assays, clinical endpoints, and emerging ulcerative colitis models without overextending the data.

• Valemetostat (DS-3201) Research Workflows

  2026-09-11

  Learn how to deploy Valemetostat (DS-3201) in EZH2 biochemical, cellular, and translational lymphoma studies. The workflow emphasizes mutant-aware assay design, solvent control, chromatin biomarkers, and metabolic readouts inspired by a mechanistically rigorous liver-injury study.

• Candida EVs, Nrg1, and Candidemia

  2026-09-10

  The reference study identifies a concentration- and time-dependent role for Candida albicans extracellular vesicles in suppressing hyphal development through the SKO1–NRG1 regulatory axis. Its mutant, transcriptomic, clinical-isolate, and mouse-infection experiments connect vesicle cargo activity with reduced fungal virulence, while also defining important limits for translation.

• Betaine Hydrochloride in Inflammation Assays

  2026-09-10

  Use Betaine hydrochloride as a controlled assay variable, soluble buffer component, or exploratory culture supplement—not as a substitute for the oridonin intervention studied in esophageal cancer. This workflow connects rigorous reagent handling with TLR4/NF-κB/NLRP3-focused biochemical, cellular, and molecular readouts.

• PPARγ Activation in DSS-Induced Inflammatory Bowel Disease

  2026-09-09

  This study links PPARγ activation to macrophage polarization and intestinal protection in a dextran sulfate sodium model of inflammatory bowel disease. Its combined cellular and animal design supports a STAT-1/STAT-6 mechanism, while also highlighting the limits of translating acute murine findings to human disease.

• Pterostilbene Delays Dermal Fibroblast Senescence

  2026-09-09

  Zhou et al. show that pterostilbene mitigates senescence in human dermal fibroblasts by improving mitochondrial quality and promoting mitophagy. Using cellular and mouse models, the study connects mitochondrial remodeling with restored respiration, collagen preservation, and reduced senescence-associated signaling.

• Troglitazone Workflows for PPARγ and SPP1

  2026-09-08

  Use Troglitazone as a practical PPARγ agonist comparator in metabolic assays, SPP1-high macrophage screens, and renal carcinoma studies. This workflow separates established receptor pharmacology from the still exploratory question of whether PPAR modulation can reprogram tumor-associated myeloid cells.

8178 records 4/546 page Previous Next 12345 下5页 Last page